Clinical Trial

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
The decision is based on strategic deprioritization and is not related to any safety concerns.
Summary
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-18; most recent amendment 2026-07-20.
Status change: Suspended → Terminated 2026-07-20
Status change: Recruiting → Suspended 2026-02-17
Status change: Not Yet Recruiting → Recruiting 2026-01-12
Trial Details
NCT Number NCT07247292
Lead Sponsor AstraZeneca
Conditions Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Enrollment 3 participants
Start Date 2025-12-23
Primary Completion 2026-02-26 (estimated)
Study Completion 2026-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-21